Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3152 participants
OBSERVATIONAL
2023-01-30
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Disease Loads and Status of Treatment
NCT05264272
HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection
NCT06264583
Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China
NCT05451082
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
NCT05394623
Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection
NCT01350648
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HDV cohort
Chronic Hepatitis B (HBsAg+) with cirrhosis (APRI \>1.5, FIB-4 \> 3.25, Fibroscan \> 12.5, imaging), PWID with HBV, HIV/HBV, HBV/HCV, aged 18 years and older
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Chronically-infected with HBV, as defined by:
Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result
3. Provide signed and dated informed consent form.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Chulalongkorn Memorial Hospital
OTHER
Thai Red Cross AIDS Research Centre
OTHER
Siriraj Hospital
OTHER
Taksin Hospital
UNKNOWN
Gilead Sciences
INDUSTRY
The HIV Netherlands Australia Thailand Research Collaboration
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anchalee Avihingsanon, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
HIV-NAT, Thai Red Cross - AIDS Research Centre
Pisit Tangkijvanich, MD
Role: PRINCIPAL_INVESTIGATOR
Biochemistry, Faculty of Medicine, Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HIV-NAT, Thai Red Cross - AIDS Research Centre
Bangkok, Bangkok, Thailand
King memorial Chulalongkorn hospital
Bangkok, Bangkok, Thailand
Siriraj Hospital, Mahidol University
Bangkok, Bangkok, Thailand
Taksin Hospital
Bangkok, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tawesak Tanwandee, MD
Role: primary
Supunee Jirajariyavej, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HIV-NAT 304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.